Vaccine company Valneva SE (Nasdaq:VALN) (Euronext Paris:VLA) and biopharmaceutical company Pfizer Inc (NYSE:PFE) on Tuesday announced positive data from a Phase 2 study of their Lyme disease vaccine candidate, VLA15.
The study evaluated the immune response and safety profile after a second booster dose.
Results showed a strong immune response and favourable safety profile in all age groups. Seroconversion rates were high, indicating effective protection against Lyme disease.
VLA15 is currently in Phase 3 clinical trials and could potentially be approved in 2026.
Valneva licenses Shigella vaccine candidate from LimmaTech
myTomorrows names new director
GSK's Arexvy receives positive CHMP opinion for at-risk adults aged 50-59
Latigo Biotherapeutics names new chief executive officer
Valneva receives CEPI funding to boost access to world's first chikungunya vaccine
Bavarian Nordic's chikungunya vaccine receives validation from EMA for accelerated review
GSK secures global rights to CureVac's mRNA vaccines in new licensing deal
INOVIO names new chief commercial officer
Dynavax Technologies commences dosing in Z-1018 phase 1/2 clinical trial
Bavarian Nordic files for chikungunya vaccine approval in Europe
Valneva's chikungunya vaccine IXCHIQ approved by Health Canada
Philippine lawmakers call for probe into secret US propaganda operation